Clene

Clene Inventory Turnover

The Inventory Turnover Ratio of Clene (CLNN) as of Oct 16, 2026 is 1.16. In the previous year, Inventory Turnover Ratio was 1.03 — a change of 12.90% (higher).

Inventory Turnover

1.16

YoY

12.90%

Last updated:

Inventory Turnover Ratio of Clene is 2025 1.16 . Inventory Turnover Ratio of Clene was 2024 1.03 . It decreases by 12.90% higher compared to the previous year.

The Clene Inventory Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory Turnover
Date
Inventory Turnover
Jan 1, 2019
32.14 USD
Jan 1, 2020
0.34 USD
Jan 1, 2021
7.05 USD
Jan 1, 2022
0.60 USD
Jan 1, 2023
3.27 USD
Jan 1, 2024
1.03 USD
Jan 1, 2025
1.16 USD
The Clene Inventory Turnover history
YEARInventory TurnoverYoY
1.16+12.90%
1.03-68.52%
3.27+440.85%
0.60-91.42%
7.05+1,971.26%
0.34-98.94%
32.14—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, operating within the health care sector and specifically in the biotechnology industry. The company went public via an IPO on August 27, 2018, and currently employs 75 full-time staff. Clene focuses on developing therapeutics for neurodegenerative diseases, with its primary drug candidate being CNM-Au8, an oral suspension of gold nanocrystals. The company's research targets energetic failure, an underlying factor in many neurological conditions, aiming to restore neuronal health and function by enhancing energy production and utilization. CNM-Au8 works through catalytically active nanocrystals that support cellular energy processes, promoting neuroprotection and remyelination by improving resilience to disease-related stressors. The company also has other product candidates, including CNM-ZnAg, a spectrum antiviral and antibacterial agent composed of zinc and silver ions, and CNM-AgZn17, a gel polymer suspension of zinc and silver designed for treating infectious diseases and supporting wound healing. Clene's website is https://clene.com/ and it is listed under the ticker CLNN with ISIN US1856342019. The company remains in the clinical development phase, focusing on advancing its pipeline of treatments for neurological and infectious conditions. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Inventory Turnover Ratio of Clene is 1.16 in 2025.

Inventory Turnover Ratio of Clene changed from 1.03 to 1.16, representing a 12.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory Turnover Ratio Clene since 2006 – with annual values, charts, and detailed analysis.

Inventory turnover measures how many times inventory is sold and replaced during a period. Higher turnover indicates efficient inventory management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Inventory Turnover Ratio's Clene with sector peers and the industry average to assess whether it is attractive.

To evaluate Inventory Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Inventory Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Clene

All Key Metrics — Clene